OnWednesday, Amphastar Pharmaceuticals said Momenta Pharmaceuticals Inc and Novartis AG’s Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.
The settlement ends an appeal by Momenta and Sandoz of a Boston federal jury’s 2017 verdict finding that a patent they claimed Amphastar infringed was invalid, a decision that exposed them to losing $100 million that they had posted as a bond earlier in the litigation.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.249
Please verify email or join us
to access premium content!
